Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DENNIS M LACEY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1083696082
CMS profile
230491
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,962.04

91 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,950.25 86
Travel and Lodging $900.63 3
Education $111.16 2

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DENNIS M LACEY

NPI 1083696082 · CMS profile ID 230491

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083696082?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DENNIS M LACEY, NPI 1083696082, CMS profile ID 230491. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083696082?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DENNIS M LACEY, NPI 1083696082, CMS profile ID 230491. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083696082?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DENNIS M LACEY, NPI 1083696082, CMS profile ID 230491, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1083696082?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

91 matching records · $2,962.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 91 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–91 of 91.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $21.5805/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908089184 CMS
Kyowa Kirin, Inc. $19.9105/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905043625 CMS
ACADIA Pharmaceuticals Inc $19.9505/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952386627 CMS
Biogen, Inc. $24.3005/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923447933 CMS
ABBVIE INC. $9.7405/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893124607 CMS
Grifols USA, LLC $15.5804/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918669153 CMS
Biogen, Inc. $18.0004/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923445245 CMS
Novartis Pharmaceuticals Corporation $18.3604/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893867295 CMS
Kyowa Kirin, Inc. $19.8504/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905043615 CMS
ABBVIE INC. $7.9104/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893124605 CMS
Teva Pharmaceuticals USA, Inc. $13.1604/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954521080 CMS
UCB, Inc. $19.0704/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908089177 CMS
Biogen, Inc. $19.2404/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923437191 CMS
Novartis Pharmaceuticals Corporation $20.0803/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893867291 CMS
Genentech USA, Inc. $13.5403/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950789607 CMS
Lilly USA, LLC $25.3503/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918001323 CMS
Biogen, Inc. $12.5903/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923430545 CMS
Avion Pharmaceuticals $23.3303/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926515853 CMS
UCB, Inc. $21.0603/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908089181 CMS
ABBVIE INC. $22.3803/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893124603 CMS
EMD Serono, Inc. $12.2603/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941500539 CMS
Lundbeck LLC $19.3103/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945770551 CMS
Mylan Specialty L.P. $24.9403/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963897947 CMS
JAZZ PHARMACEUTICALS INC. $20.1203/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954284453 CMS
JAZZ PHARMACEUTICALS INC. $20.1203/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954284455 CMS
Acorda Therapeutics, Inc $18.8402/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920333515 CMS
Biohaven Pharmaceutical Holding Company Ltd. $11.8902/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923646605 CMS
IMPEL PHARMACEUTICALS INC. $12.1602/18/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962311849 CMS
ABBVIE INC. $17.1002/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893124601 CMS
Biogen, Inc. $17.8302/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923415811 CMS
UCB, Inc. $24.9302/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908089187 CMS
ABBVIE INC. $3.0302/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893124599 CMS
Lundbeck LLC $18.4702/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945770547 CMS
Amgen Inc. $19.8202/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946544211 CMS
Biohaven Pharmaceutical Holding Company Ltd. $15.3501/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923646603 CMS
Novartis Pharmaceuticals Corporation $24.3201/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893867287 CMS
Teva Pharmaceuticals USA, Inc. $17.2801/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954521039 CMS
ABBVIE INC. $15.3401/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893124597 CMS
Biogen, Inc. $22.8301/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923397155 CMS
Kyowa Kirin, Inc. $17.9201/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905043611 CMS
Lundbeck LLC $30.3001/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945770543 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,184.07 80
PY2020 $1,937.36 120
PY2021 $2,659.74 165
PY2022 $2,962.04 91
PY2023 $1,569.11 76
PY2024 $1,999.24 55
PY2025 $1,141.11 46

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $540,513.70 223
PY2024 Recipient $3,195.00 1
PY2024 Principal investigator $954,682.55 188
PY2023 Principal investigator $214,495.51 25
PY2022 Recipient $20,313.00 2
PY2022 Principal investigator $405,410.12 84
PY2021 Principal investigator $290,845.28 44
PY2020 Principal investigator $404,490.65 76
PY2019 Principal investigator $15,372.12 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

223 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $70.00 12/22/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624130
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,621.41 12/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223289664
Principal investigator 1 Alkermes, Inc. $37.60 12/08/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615049
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,812.57 12/01/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223289001
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741220
Principal investigator 1 Alkermes, Inc. $3,512.00 11/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617539
Principal investigator 1 Alkermes, Inc. $806.00 11/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619915
Principal investigator 1 Alkermes, Inc. $324.00 11/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621008
Principal investigator 1 Alkermes, Inc. $400.00 11/10/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616063
Principal investigator 1 Alkermes, Inc. $2,347.00 11/10/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618493
Principal investigator 1 Alkermes, Inc. $2,347.00 11/10/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622073
Principal investigator 1 Alkermes, Inc. $1.10 11/10/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624532
Principal investigator 1 Alkermes, Inc. $650.00 10/27/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616285
Principal investigator 1 Alkermes, Inc. $1,800.00 10/27/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617369
Principal investigator 1 Alkermes, Inc. $1,500.00 10/27/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621222
Principal investigator 1 Alkermes, Inc. $615.00 10/27/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626678
Principal investigator 1 Alkermes, Inc. $3,500.00 10/15/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618489
Principal investigator 1 Alkermes, Inc. $3,500.00 10/13/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617543
Principal investigator 1 Alkermes, Inc. $126.00 10/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617989
Principal investigator 1 Alkermes, Inc. $186.00 10/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626912
Principal investigator 1 Alkermes, Inc. $2,800.00 09/08/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615747
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,400.00 09/04/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232946292
Principal investigator 1 Vanda Pharmaceuticals Inc. $400.00 09/04/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232946296
Principal investigator 1 Alkermes, Inc. $56.40 09/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616165
Principal investigator 1 Alkermes, Inc. $150.00 09/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621742
Principal investigator 1 Alkermes, Inc. $75.20 09/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622797
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623952
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623954
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625956
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,827.98 08/21/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741218
Principal investigator 1 Alkermes, Inc. $7,793.00 08/20/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623756
Principal investigator 1 Alkermes, Inc. $70.00 08/13/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623914
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,712.49 08/08/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283983
Principal investigator 1 Alkermes, Inc. $5,048.00 08/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614056
Principal investigator 1 Alkermes, Inc. $7,281.00 08/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626818
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,390.00 08/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223283857
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,049.00 08/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223283859
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,016.00 08/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223283861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $973.00 08/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223283863
Principal investigator 1 Alkermes, Inc. $1,600.00 07/28/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616187
Principal investigator 1 Alkermes, Inc. $2,800.00 07/28/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624202
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 07/28/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741214
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 07/28/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741216
Principal investigator 1 Alkermes, Inc. $1,200.00 07/11/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616613
Principal investigator 1 Alkermes, Inc. $327.00 07/09/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624883
Principal investigator 1 Alkermes, Inc. $800.00 07/02/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622817
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613409
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613611
Principal investigator 1 Alkermes, Inc. $8.56 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614298
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614489
Principal investigator 1 Alkermes, Inc. $192.75 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614947
Principal investigator 1 Alkermes, Inc. $115.65 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614951
Principal investigator 1 Alkermes, Inc. $27.82 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615345
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615683
Principal investigator 1 Alkermes, Inc. $100.30 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615765
Principal investigator 1 Alkermes, Inc. $93.50 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615921
Principal investigator 1 Alkermes, Inc. $8.04 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615939
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617067
Principal investigator 1 Alkermes, Inc. $103.10 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617079
Principal investigator 1 Alkermes, Inc. $5.95 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617665
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617683
Principal investigator 1 Alkermes, Inc. $25.70 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618141
Principal investigator 1 Alkermes, Inc. $37.24 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618161
Principal investigator 1 Alkermes, Inc. $8.56 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618167
Principal investigator 1 Alkermes, Inc. $1.09 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618631
Principal investigator 1 Alkermes, Inc. $36.40 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619321
Principal investigator 1 Alkermes, Inc. $15.68 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619499
Principal investigator 1 Alkermes, Inc. $4.28 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619601
Principal investigator 1 Alkermes, Inc. $2.80 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619825
Principal investigator 1 Alkermes, Inc. $103.10 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620083
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620219
Principal investigator 1 Alkermes, Inc. $38.55 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620273
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620291
Principal investigator 1 Alkermes, Inc. $2.80 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620938
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621088
Principal investigator 1 Alkermes, Inc. $25.70 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621138
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621276
Principal investigator 1 Alkermes, Inc. $1.05 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621780
Principal investigator 1 Alkermes, Inc. $218.40 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622215
Principal investigator 1 Alkermes, Inc. $16.08 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622573
Principal investigator 1 Alkermes, Inc. $109.20 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622841
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623342
Principal investigator 1 Alkermes, Inc. $6.65 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624224
Principal investigator 1 Alkermes, Inc. $21.40 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624250
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624668
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625117
Principal investigator 1 Alkermes, Inc. $515.50 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625119
Principal investigator 1 Alkermes, Inc. $9.35 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625237
Principal investigator 1 Alkermes, Inc. $17.10 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625473
Principal investigator 1 Alkermes, Inc. $8.04 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625517
Principal investigator 1 Alkermes, Inc. $8.04 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626128
Principal investigator 1 Alkermes, Inc. $33.32 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626210
Principal investigator 1 Alkermes, Inc. $109.20 06/18/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626822
Principal investigator 1 Alkermes, Inc. $20.00 06/08/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613069
Principal investigator 1 Alkermes, Inc. $19.41 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613812
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614002
Principal investigator 1 Alkermes, Inc. $136.80 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618637
Principal investigator 1 Alkermes, Inc. $220.78 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619751
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620215
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620443
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621090
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621494
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624146
Principal investigator 1 Alkermes, Inc. $135.00 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625247
Principal investigator 1 Alkermes, Inc. $12.48 06/06/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626266
Principal investigator 1 Alkermes, Inc. $2,369.00 06/04/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615379
Principal investigator 1 Alkermes, Inc. $294.00 05/27/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617505
Principal investigator 1 Alkermes, Inc. $276.00 05/16/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618667
Principal investigator 1 Alkermes, Inc. $756.00 05/16/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620313
Principal investigator 1 Alkermes, Inc. $808.28 05/09/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626756
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 05/09/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223279334
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,958.49 05/09/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223279374
Principal investigator 1 Alkermes, Inc. $2,400.00 05/07/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613641
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,700.00 05/07/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945360
Principal investigator 1 Vanda Pharmaceuticals Inc. $8,100.00 05/07/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945364
Principal investigator 1 Alkermes, Inc. $1,562.00 05/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616669
Principal investigator 1 Alkermes, Inc. $327.00 05/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617937
Principal investigator 1 Alkermes, Inc. $327.00 05/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619159
Principal investigator 1 Alkermes, Inc. $2,293.00 05/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619647
Principal investigator 1 Alkermes, Inc. $2,814.00 05/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623620
Principal investigator 1 Alkermes, Inc. $327.00 05/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624294
Principal investigator 1 Alkermes, Inc. $327.00 05/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625157
Principal investigator 1 Alkermes, Inc. $1,196.53 05/01/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615103
Principal investigator 1 Alkermes, Inc. $2,032.00 04/23/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617203
Principal investigator 1 Alkermes, Inc. $725.00 04/23/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619375
Principal investigator 1 Alkermes, Inc. $7,793.00 04/23/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623470
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,400.00 04/23/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945223
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,000.00 04/23/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945227
Principal investigator 1 Alkermes, Inc. $2,276.00 04/21/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613707
Principal investigator 1 Alkermes, Inc. $1,045.00 04/21/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622994
Principal investigator 1 Alkermes, Inc. $2,094.00 04/21/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623838
Principal investigator 1 Alkermes, Inc. $1,200.00 04/14/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619687
Principal investigator 1 Alkermes, Inc. $150.00 04/14/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621022
Principal investigator 1 Alkermes, Inc. $147.00 04/14/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623658
Principal investigator 1 Alkermes, Inc. $4,500.00 04/07/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613219
Principal investigator 1 Alkermes, Inc. $300.00 04/07/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620764
Principal investigator 1 Alkermes, Inc. $1,200.00 04/07/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621690
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $120.51 03/07/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223276145
Principal investigator 1 Alkermes, Inc. $47.75 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613721
Principal investigator 1 Alkermes, Inc. $35.20 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613956
Principal investigator 1 Alkermes, Inc. $38.55 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616335
Principal investigator 1 Alkermes, Inc. $259.54 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617161
Principal investigator 1 Alkermes, Inc. $38.55 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618031
Principal investigator 1 Alkermes, Inc. $119.36 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621040
Principal investigator 1 Alkermes, Inc. $47.75 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621666
Principal investigator 1 Alkermes, Inc. $56.85 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622103
Principal investigator 1 Alkermes, Inc. $50.15 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623204
Principal investigator 1 Alkermes, Inc. $8.80 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623206
Principal investigator 1 Alkermes, Inc. $113.34 03/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623208
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,700.00 02/25/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232944856
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615359
Principal investigator 1 Alkermes, Inc. $650.00 02/13/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616237
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619361
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619617
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621827
Principal investigator 1 Alkermes, Inc. $650.00 02/13/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624500
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624696
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625866
Principal investigator 1 Alkermes, Inc. $324.00 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613001
Principal investigator 1 Alkermes, Inc. $167.05 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613293
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613723
Principal investigator 1 Alkermes, Inc. $128.50 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615235
Principal investigator 1 Alkermes, Inc. $2,133.00 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616229
Principal investigator 1 Alkermes, Inc. $89.95 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616297
Principal investigator 1 Alkermes, Inc. $15.39 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616321
Principal investigator 1 Alkermes, Inc. $50.15 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616547
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616959
Principal investigator 1 Alkermes, Inc. $25.70 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617377
Principal investigator 1 Alkermes, Inc. $25.70 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618941
Principal investigator 1 Alkermes, Inc. $52.80 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619231
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620389
Principal investigator 1 Alkermes, Inc. $25.00 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621032
Principal investigator 1 Alkermes, Inc. $0.85 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621038
Principal investigator 1 Alkermes, Inc. $206.20 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621664
Principal investigator 1 Alkermes, Inc. $6.40 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622095
Principal investigator 1 Alkermes, Inc. $7.69 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623672
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625680
Principal investigator 1 Alkermes, Inc. $1.71 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625682
Principal investigator 1 Alkermes, Inc. $9.00 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626486
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626710
Principal investigator 1 Alkermes, Inc. $228.53 02/10/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623882
Principal investigator 1 Alkermes, Inc. $82.08 02/10/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624352
Principal investigator 1 Alkermes, Inc. $77.64 02/10/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624558
Principal investigator 1 Alkermes, Inc. $52.48 02/10/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626712
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 02/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223274911
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,400.00 02/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223274913
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 02/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223274915
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $741.00 02/05/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223274917
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,797.92 02/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741202
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,268.88 02/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741204
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,268.88 02/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741206
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,869.12 02/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741208
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,797.92 02/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741210
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,268.88 02/03/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741212
Principal investigator 1 Eli Lilly and Company $150.00 01/31/2025 Non-covered Recipient Entity
DR DENNIS M LACEY
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) No dispute reported 06/30/2026 1187879865
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
DR DENNIS M LACEY
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187881146
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,500.00 01/29/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223274559
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $375.00 01/29/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223274561
Principal investigator 1 Alkermes, Inc. $3,578.00 01/22/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616867
Principal investigator 1 Alkermes, Inc. $1,347.00 01/22/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619133
Principal investigator 1 Alkermes, Inc. $575.00 01/22/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619843
Principal investigator 1 Alkermes, Inc. $2,616.00 01/22/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622227
Principal investigator 1 Alkermes, Inc. $364.00 01/22/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624034
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,868.87 01/22/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223274413
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 01/22/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223274415
Principal investigator 1 Vanda Pharmaceuticals Inc. $4,000.00 01/22/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232944602
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,500.00 01/22/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH INC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232944606
Principal investigator 1 Eli Lilly and Company $160,784.00 01/21/2025 Non-covered Recipient Entity
DR DENNIS M LACEY
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) No dispute reported 06/30/2026 1187881144
Principal investigator 1 Alkermes, Inc. $1,914.00 01/17/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614993
Principal investigator 1 Alkermes, Inc. $349.00 01/17/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616013
Principal investigator 1 Alkermes, Inc. $349.00 01/17/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617923
Principal investigator 1 Alkermes, Inc. $2,284.00 01/17/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620742
Principal investigator 1 Alkermes, Inc. $806.00 01/17/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622643
Principal investigator 1 Alkermes, Inc. $860.00 01/17/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623790
Principal investigator 1 Alkermes, Inc. $2,133.00 01/17/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625365
Principal investigator 1 Alkermes, Inc. $324.00 01/17/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625597
Principal investigator 1 Alkermes, Inc. $2,007.00 01/17/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625830
Principal investigator 1 Eli Lilly and Company $734.77 01/14/2025 Non-covered Recipient Entity
DR DENNIS M LACEY
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187878867
Principal investigator 1 Eli Lilly and Company $94,266.38 01/07/2025 Non-covered Recipient Entity
DR DENNIS M LACEY
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187879967
Principal investigator 1 Eli Lilly and Company $40,922.42 01/07/2025 Non-covered Recipient Entity
DR DENNIS M LACEY
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187879969
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627082
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627160
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
NEUROTRIALS RESEARCH, INC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627232